CELZ - Creative Medical Technology Holdings: Initiating Coverage With A Sell Rating
2025-05-12 15:59:35 ET
Summary
- Initiating coverage on Creative Medical Technology Holdings with a Sell rating due to early-stage pipeline and significant downside risks outweighing potential upside.
- The company’s pipeline includes AlloStem for diabetes, AlloStemSpine for back pain, and OvaStem for infertility, all in early development with high uncertainty.
- Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing, posing significant risks to current shareholders.
- Competing therapies from larger companies in diabetes and back pain markets could overshadow Creative Medical’s offerings, making commercial success uncertain.
Introduction
We are initiating coverage on Creative Medical Technology Holdings ( CELZ ) with a Sell rating. Creative Medical is a small clinical-stage biotech focusing on cell therapies for diabetes, immune disorders, orthopedic and gynecologic diseases. The company has a pipeline of regenerative medicine products, but all are in early development stages with significant uncertainty and are targeting markets with intense competition, in our opinion. ...
Creative Medical Technology Holdings: Initiating Coverage With A Sell Rating